Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort - 22025 Was Another Exceptionally Hot Year
- 3Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- 4A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- 5Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- 5 Bike Brands for Ordinary Use
- Polls open in tense Uganda election amid widespread delays
- US healthcare spending soars to over $5 trillion in 2024
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
